Keryx Biopharmaceuticals
750 Lexington Avenue, 26th Floor
New York
New York
10022
United States
Tel: 212-531-5965
Fax: 212-531-5961
Website: http://www.keryx.com/
386 articles about Keryx Biopharmaceuticals
-
Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company
12/13/2018
Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger.
-
Akebia Therapeutics Shareholders Approve Merger with Keryx
12/11/2018
Akebia Therapeutics, Inc. today announced that Akebia shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) at a special meeting of Akebia shareholders held earlier today. More than 95% of the shares voted at the special meeting voted in favor of the share issuance proposal.
-
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
11/30/2018
Akebia Therapeutics, Inc. (Nasdaq:AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (“Glass Lewis”), joins Institutional Shareholder Services (“ISS”) in recommending that Akebia shareholders vote “FOR” the shareholder proposals relating to the Company’s proposed merger with Keryx Biopharmaceuticals (Nasdaq:KERX).
-
Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
11/29/2018
Akebia Urges Shareholders to Vote “FOR” the Merger-Related Shareholder Proposals Today
-
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
11/15/2018
Adrian Adams To Serve as Independent Chairperson of the Board After Merger
-
Akebia Therapeutics Sends Letter to Shareholders
11/13/2018
Recommends Shareholders Vote “FOR” the Proposals Relating to the Merger
-
Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
10/30/2018
Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that it and Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) filed a definitive joint proxy statement with the U.S. Securities and Exchange Commission (“SEC”)
-
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
-
WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.
6/30/2018
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc.
-
Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
6/28/2018
Expects to Capture Significant Operating and Product Portfolio Synergies, Accelerating Revenue Growth and Creating Shareholder Value.
-
Shares of Akebia Therapeutics are up more than 10 percent in premarket trading after the company announced it struck a merger agreement with Keryx Biopharmaceuticals, Inc. to create a company expected to be a leader in the development of renal disease therapies.
-
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
2/7/2018
The company also reviewed its commercial progress with Auryxia following approval of the medicine’s second indication for the treatment of iron deficiency anemia in adults with chronic kidney disease, not on dialysis.
-
Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018
2/5/2018
To participate in the conference call, please dial 1-888-396-2320 (U.S.)
-
The deal was originally inked on Jan 17, 2014.
-
Keryx Biopharma and Siegfried Enter Into a Master Manufacturing Services and Supply Agreement
12/27/2017
The Agreement has an initial term ending on December 31, 2021 and will automatically renew after that for successive terms of one year each.
-
BioVectra and Keryx Biopharma Enter Agreement for Ferric Citrate Production Expansion
12/14/2017
BioVectra today announced a long-term supply agreement with Keryx Biopharma to manufacture Ferric Citrate, the API in Auryxia tablets.
-
Biotech companies have a number of pivotal challenges in going from a promising compound to commercially viable products.
-
Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ET
11/7/2017
To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 2193619.
-
Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results
11/7/2017
Approximately 24,900 Auryxia prescriptions were written in the third quarter of 2017, representing 18 percent growth over the second quarter of 2017.
-
U.S. FDA Approves Keryx Biopharma's Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
11/7/2017
Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia and chronic kidney disease, not on dialysis.